Function, work productivity, and quality of life measures in a phase 3, randomized, placebo-controlled, double-blind, multicenter, 12-week study of the safety and efficacy of solriamfetol (JZP-110) for the treatment of excessive sleepiness in patients with obstructive sleep apnea